Target intelligence / Profile preview

Glycoprotein L (gL)

Target
gL
Molecular classification
Viral envelope glycoprotein, Entry/fusion complex component, Herpesvirus fusion protein partner (forms a heterodimer with glycoprotein H, gH)
01

Overview

Glycoprotein L (gL) is an essential viral envelope protein found in all herpesviruses; it forms a tightly associated heterodimer with glycoprotein H (gH), creating the gH/gL complex that controls membrane fusion, a critical step for viral entry into host cells[5][4][8]. Unlike gH, gL lacks a transmembrane region and is necessary for the correct folding, trafficking, and function of gH; together, the complex orchestrates fusion via direct activation of glycoprotein B (gB)[5]. The gH/gL complex also mediates receptor engagement—such as binding integrins for epithelial infection—making gL a target for neutralizing antibodies and fusion-blocking interventions[4][8]. The protein is highly conserved among herpesviruses, with some species-specific differences influencing host tropism and immune targeting[4][5][8]. It is not a human receptor/enzyme, but belongs to the “viral glycoprotein—entry/fusion machinery” molecular class, and as such, is a validated target for antiviral research and mechanistic studies in viral pathogenesis.

Other names
gLHerpesvirus glycoprotein LEpstein-Barr virus glycoprotein LHSV-1/2 glycoprotein LVaricella-zoster virus glycoprotein L
02

Mechanism of action

Inhibition of the gH/gL/gB complex formation or function; Neutralizing antibody blockade of protein-protein interaction or conformational transition needed for fusion; Blocking interaction with cell surface receptors (e.g., integrins or others)

03

Biological functions

Virus entry (membrane fusion activation)Protein-protein interaction (formation/transport of gH/gL complex)Cell surface targeting of fusion complexRecruitment/activation of glycoprotein B (gB) for membrane fusion
04

Disease associations

InfectionCancerVirus-mediated cell fusion
05

Safety considerations

Therapeutic challenge: Highly conserved structure limits selectivity for specific virus strainsPotential off-target immune responses if using biologics targeting gL, especially in vaccine or antibody therapy
06

Interacting drugs

No approved drugs directly target gL; however, experimental neutralizing antibodies and fusion inhibitors against herpesvirus entry machinery (including targeting gH/gL or its interaction with cell receptors/gB) are under investigation

1 more in the full profile.

07

Biomarkers

Presence/sequence of gL gene in viral genomeViral entry efficiency

Beyond the preview

Go deeper on Glycoprotein L (gL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycoprotein L (gL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call